Business Standard

Cipla shares gain 5% after USFDA okays capsules; m-cap rises by Rs 3,021 cr

The stock jumped 5.10 per cent to close at Rs 770.20 on the BSE. During the day, it rose by 5.97 per cent to Rs 776.60.

v
Premium

The newly approved product is a generic therapeutic equivalent version of Biogen IDEC Inc's Tecfidera.

Press Trust of India Mumbai
Shares of drug firm Cipla on Friday gained over 5 per cent after the company said it has received the final approval from the US health regulator for Dimethyl Fumarate capsules.

The stock jumped 5.10 per cent to close at Rs 770.20 on the BSE. During the day, it rose by 5.97 per cent to Rs 776.60.

On the NSE, it gained 4.99 per cent to settle at Rs 770.10.

The company's market valuation also rose by Rs 3,021.11 crore to Rs 62,104.11 crore.

The newly approved product is a generic therapeutic equivalent version of Biogen IDEC Inc's Tecfidera.

Cipla

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 25 2020 | 8:36 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com